GlassScriptPhysician profile
Shannon Cislo
NPI 1821719899
$1,947.24
in general payments reported to CMS, 2019-2025
24 companies · $641 in 2025
The $641 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $13.83 · 2023: $422 · 2024: $870 · 2025: $641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,933.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,933.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $327.32 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $245.78 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $199.38 | 2023-2025 | Keytruda, Vaxneuvance, Gardasil 9 |
| Glaxosmithkline, LLC. | $183.16 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Pfizer INC. | $174.71 | 2023-2025 | |
| Exact Sciences Corporation | $153.32 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $143.31 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.74 | 2024-2025 | |
| Daiichi Sankyo INC. | $54.09 | 2024-2025 | Injectafer |
| Xeris Pharmaceuticals, INC. | $47.17 | 2025 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $43.72 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $28.79 | 2024 | Voquezna |
| Dynavax Technologies Corporation | $23.63 | 2025 | Heplisav-B |
| Noven Therapeutics, LLC | $21.09 | 2024 | Xelstrym |
| Lilly USA, LLC | $20.41 | 2024 | Zepbound, Jardiance |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $20.07 | 2025 | Freestyle Libre 3 |
| Verrica Pharmaceuticals INC. | $20.00 | 2025 | Ycanth |
| Hologic Sales and Service, LLC | $18.20 | 2024 | Aptima |
| Sumitomo Pharma America, INC. | $17.57 | 2025 | Gemtesa |
| Tris Pharma INC | $17.33 | 2025 | Onyda Xr |
| Astellas Pharma US INC | $15.78 | 2024 | Veozah |
| Medtronic, INC. | $13.83 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.82 | 2024 | |
| Myriad Genetic Laboratories, INC. | $13.02 | 2023 | Myrisk |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Cislo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.